Hisoar Pharma To Supply Pfizer With Clindamycin HCl For 20 Years
This article was originally published in PharmAsia News
Executive Summary
China’s leading API producer Zhejiang Hisoar Pharmaceutical Co., Ltd. has signed a 20-year agreement with Pfizer Inc.’s Pfizer Asia Manufacturing Pte. Ltd.
China’s leading API producer Zhejiang Hisoar Pharmaceutical Co., Ltd. has signed a 20-year agreement with Pfizer Inc.’s Pfizer Asia Manufacturing Pte. Ltd. Hisoarwill annually supplyPfizer with 300 tons, minimum, of clindamycin hydrochloride products, and will purchase Pfizer’s technology advancement services. Other than Hisoar, Pfizer collaborates with Shanghai Pharmaceuticals Holding Co., Ltd. in areas like drug distribution, manufacturing, commercialization, and R&D in China. Last year,Hisoar’s clindamycin production costs increased 19.95%. An industry insider highlighted that rising domestic costs have caused a switch to higher-paying MNC partners and forecasted industry size reduction over the next few years. (Click Here For More - Chinese Language
)
"API Makers’ Difficulty In Switching Business; Hisoar Turns Pfizer’s Processing Contractor"- finance.laogumincj.com (7/5/2012)